Hundreds of millions of people all over the word suffer from type 2 Diabetes and the competition between pharma companies is fierce. Amongst them, Sanofi must think that good things come to those who wait. After years of delay, the French colossus is convinced with the Phase IIIb results on its type 2 diabetes treatment.
“Forewarned is forearmed”, must have thought Sanofi as Novo Nordisk struggled with the FDA’s strict requirements concerning its type 2 diabetes therapy last year. The FDA toughened the regulation process for the new generation of diabetes treatments which is why Sanofi decided to take its time designing a 5-year study for its therapy.
Patients with type 2 diabetes have lower levels and impaired action of glucagon-like peptide-1 (GLP-1). GLP-1 agonist drugs mimic the action of this hormone stimulating the body’s natural production of insulin, lowering blood sugar and body weight in the process. The drug, lixisenatide, is already commercialized in Europe under the name “Lyxumia”, despite there being no GLP-1 treatment with a proven safety profile in a long-term trial yet.